Compare · LMDX vs TNFA
LMDX vs TNFA
Side-by-side comparison of LumiraDx Limited (LMDX) and TNF Pharmaceuticals Inc. (TNFA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both LMDX and TNFA operate in Biotechnology: In Vitro & In Vivo Diagnostic Substances (Health Care), so they compete in similar markets.
- LMDX carries a market cap of $2.23B.
- LMDX has more recent analyst coverage (4 ratings vs 0 for TNFA).
- Company
- LumiraDx Limited
- TNF Pharmaceuticals Inc.
- Price
- $0.02-53.80%
- $5.17+47.50%
- Market cap
- $2.23B
- -
- 1M return
- -
- -24.75%
- 1Y return
- -
- -68.28%
- Industry
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2014
- News (4w)
- 0
- 0
- Recent ratings
- 4
- 0
Latest LMDX
- SEC Form SC 13G/A filed by LumiraDx Limited (Amendment)
- SEC Form SC 13G/A filed by LumiraDx Limited (Amendment)
- SEC Form 6-K filed by LumiraDx Limited
- 12 Health Care Stocks Moving In Monday's After-Market Session
- Dow Surges Over 100 Points; Commercial Metals Posts Upbeat Q1 Results
- Why RxSight Shares Are Trading Higher By 20%? Here Are Other Stocks Moving In Monday's Mid-Day Session
- LumiraDx shares are trading lower after the company announced its securities will be suspended from trading on Nasdaq at the open of business tomorrow.
- 12 Health Care Stocks Moving In Monday's Intraday Session
- Crude Oil Falls Sharply; Ambrx Biopharma Shares Spike Higher
- US Stocks Mixed; Nasdaq Jumps Over 100 Points
Latest TNFA
- TNF Pharmaceuticals Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits
- Q/C Technologies (Formerly TNF Pharmaceuticals) Commences Trading on Nasdaq Under New Ticker Symbol "QCLS"
- TNF Pharmaceuticals Announces Name Change to Q/C Technologies and New Ticker Symbol "QCLS" to Reflect Strategic Focus on Quantum Class Photonic Computing
- TNF Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement
- TNF Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits
- TNF Pharmaceuticals to Present at the H.C. Wainwright 27th Annual Global Investment Conference
- Amendment: TNF Pharmaceuticals Inc. filed SEC Form 8-K: Financial Statements and Exhibits
- SEC Form D filed by TNF Pharmaceuticals Inc.
- TNF Pharmaceuticals Announces Closing of $7 Million Private Placement
- TNF Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Unregistered Sales of Equity Securities, Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits